The sensitivity of acute myeloid leukemia cells to cytarabine is increased by suppressing the expression of Heme oxygenase-1 and hypoxia-inducible factor 1-alpha.

Authors: Sadeghi, Mohammad¹ (AUTHOR), Moslehi, Asma¹ (AUTHOR), Kheiry, Hadiseh¹ (AUTHOR), Kiani, Fariba Karoon¹ (AUTHOR), Zarei, Asieh¹ (AUTHOR), Khodakarami, Atefeh¹ (AUTHOR), Karpisheh, Vahid² (AUTHOR), Masjedi, Ali^3,4 (AUTHOR), Rahnama, Badrossadat¹ (AUTHOR), Hojjat-Farsangi, Mohammad⁵ (AUTHOR), Raeisi, Mortaza⁶ (AUTHOR), Yousefi, Mehdi¹ (AUTHOR), Movasaghpour Akbari, Ali Akbar⁶ (AUTHOR) movassaghpour@tbzmed.ac.ir, Jadidi-Niaragh, Farhad^1,7 (AUTHOR) jadidif@tbzmed.ac.ir

Source: Cancer Cell International. 6/25/2024, Vol. 24 Issue 1, p1-14. 14p.

Subject Terms: *CYTARABINE, *ACUTE myeloid leukemia, *MYELOID cells, *HYPOXIA-inducible factors, *HEME, *REACTIVE oxygen species

A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1.

Authors: Zhao, Kai^1,2 (AUTHOR), Braun, Madita^1,2 (AUTHOR), Meyer, Leonie^1,2 (AUTHOR), Otte, Katharina^1,2 (AUTHOR), Raifer, Hartmann³ (AUTHOR), Helmprobst, Frederik⁴ (AUTHOR), Möschl, Vincent⁴ (AUTHOR), Pagenstecher, Axel^4,5 (AUTHOR), Urban, Hans^5,6 (AUTHOR), Ronellenfitsch, Michael W.^5,6 (AUTHOR), Steinbach, Joachim P.^5,6 (AUTHOR), Pesek, Jelena⁷ (AUTHOR), Watzer, Bernhard⁷ (AUTHOR), Nockher, Wolfgang A.⁷ (AUTHOR), Taudte, R. Verena⁷ (AUTHOR), Neubauer, Andreas^2,5 (AUTHOR), Nimsky, Christopher^1,5 (AUTHOR), Bartsch, Jörg W.^1,5 (AUTHOR), Rusch, Tillmann^2,5 (AUTHOR) tillmann.rusch@uk-gm.de

Source: Cells (2073-4409). Apr2024, Vol. 13 Issue 7, p632. 25p.

Subject Terms: *VENETOCLAX, *CYTARABINE, *GLIOBLASTOMA multiforme, *DRUG efficacy, *APOPTOSIS, *CELL cycle, *BCL genes

Physiological and histological effects of apigenin and luteolin on Cytarabine injected rats.

Authors: Sultan, Omar N.¹, omaralsultan@uomosul.edu.iq, Taqa, Ghada A.¹, ghadataqa@uomosul.edu.iq

Source: Baghdad Science Journal; 2024, Vol. 21 Issue 1, p1-9, 9p

Neurodevelopmental Process Monitoring of Cytosine Arabinoside-Exposed Neurons Using Raman Spectroscopy.

Authors: Hashimoto, Kosuke^1,2 (AUTHOR) khashi@cts.u-toyama.ac.jp, Sato, Hidetoshi² (AUTHOR)

Source: Applied Spectroscopy. Mar2025, Vol. 79 Issue 3, p396-403. 8p.

Subject Terms: *PRINCIPAL components analysis, *CYTARABINE, *RAMAN spectroscopy, *NEURON development, *CHEMOMETRICS

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.

Authors: Jaramillo, Sonia¹ (AUTHOR) Sonia.jaramillosegura@med.uni-heidelberg.de, Le Cornet, Lucian² (AUTHOR), Kratzmann, Markus² (AUTHOR), Krisam, Johannes³ (AUTHOR), Görner, Martin⁴ (AUTHOR), Hänel, Mathias⁵ (AUTHOR), Röllig, Christoph⁶ (AUTHOR), Wass, Maxi⁷ (AUTHOR), Scholl, Sebastian⁸ (AUTHOR), Ringhoffer, Mark⁹ (AUTHOR), Reichart, Alexander¹⁰ (AUTHOR), Steffen, Björn¹¹ (AUTHOR), Kayser, Sabine¹² (AUTHOR), Mikesch, Jan-Henrik¹³ (AUTHOR), Schaefer-Eckart, Kerstin¹⁴ (AUTHOR), Schubert, Jörg¹⁵ (AUTHOR), Geer, Thomas¹⁶ (AUTHOR), Martin, Sonja¹⁷ (AUTHOR), Kieser, Meinhard¹⁷ (AUTHOR), Sauer, Tim¹ (AUTHOR)

Source: Trials. 9/15/2023, Vol. 24 Issue 1, p1-15. 15p. 3 Charts, 1 Graph.

Subject Terms: *CYTARABINE, *HEMATOPOIETIC stem cell transplantation, *ACUTE myeloid leukemia, *OLDER patients, *MITOXANTRONE, *SALVAGE therapy

Transcriptional Response to Standard AML Drugs Identifies Synergistic Combinations.

Authors: More, Piyush¹ (AUTHOR) joelle.mekontso@leibniz-inm.de, Ngaffo, Joëlle Aurelie Mekontso^1,2 (AUTHOR) goedtela@uni-mainz.de, Goedtel-Armbrust, Ute¹ (AUTHOR) wojnowsk@uni-mainz.de, Hähnel, Patricia S.^3,4 (AUTHOR) p.haehnel@uni-mainz.de, Hartwig, Udo F.^4,5 (AUTHOR), Kindler, Thomas^3,4 (AUTHOR) thomas.kindler@unimedizin-mainz.de, Wojnowski, Leszek¹ (AUTHOR)

Source: International Journal of Molecular Sciences. Aug2023, Vol. 24 Issue 16, p12926. 17p.

Subject Terms: *CYTARABINE, *DRUG standards, *GENE expression profiling, *ACUTE myeloid leukemia, *GENE expression, *OLDER patients

Treatment of Langerhans cell histiocytosis with subcutaneous cytarabine.

Authors: Eckstein, Olive S.¹ (AUTHOR), Bernhardt, M. Brooke¹ (AUTHOR), Hood, Chelsey G.¹ (AUTHOR), Karri, Vivekanudeep¹ (AUTHOR), Kralik, Stephen F.² (AUTHOR), McClain, Kenneth L.¹ (AUTHOR)

Source: Pediatric Hematology & Oncology. Jul2023, Vol. 40 Issue 5, p497-505. 9p.

Subject Terms: *LANGERHANS-cell histiocytosis, *CYTARABINE, *DIABETES insipidus, *SUBCUTANEOUS infusions, *ARTERIAL catheterization, *BONE diseases

Synergistic anticancer effect of polymersome‐encapsulated curcumin and cytarabine: A spectroscopic and theoretical approach.

Authors: Das, Debashree¹, Bhattacharya, Sampurna², Ganguly, Sreshtha³, Sur, Runa², Sen, Kamalika¹, kamalchem.roy@gmail.com

Source: Journal of Applied Polymer Science; 11/5/2024, Vol. 141 Issue 41, p1-14, 14p

Methotrexate and cytarabine in adult LCH: High risk, high reward and maintenance free?

Authors: Abeykoon, Jithma P.¹ (AUTHOR), Go, Ronald S.¹ (AUTHOR) go.ronald@mayo.edu, Azoulay, Levi‐Dan² (AUTHOR), Haroche, Julien³ (AUTHOR)

Source: British Journal of Haematology. Feb2025, Vol. 206 Issue 2, p792-794. 3p.

Subject Terms: *METHOTREXATE, *CYTARABINE, *CANCER chemotherapy, *LANGERHANS-cell histiocytosis, *INDIVIDUALIZED medicine, *TREATMENT effectiveness, *CLINICAL trials, *OLDER patients

A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China.

Authors: Li, Wei¹ (AUTHOR) liwei1988hust@126.com, Wan, Li¹ (AUTHOR)

Source: PLoS ONE. 6/1/2023, Vol. 18 Issue 6, p1-16. 16p.

Subject Terms: *COST effectiveness, *CYTARABINE, *NON-small-cell lung carcinoma, *PLACEBOS, *TERMINAL care, *MEDICAL care costs

Geographic Terms: CHINA

A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1.

Authors: Numata, Masashi¹ (AUTHOR), Haginoya, Noriyasu² (AUTHOR), Shiroishi, Machiko¹ (AUTHOR), Hirata, Tsuyoshi² (AUTHOR), Sato-Otsubo, Aiko^3,4 (AUTHOR), Yoshikawa, Kenji¹ (AUTHOR), Takata, Yoshimi¹ (AUTHOR), Nagase, Reina¹ (AUTHOR), Kashimoto, Yoshinori² (AUTHOR), Suzuki, Makoto² (AUTHOR), Schulte, Nina⁵ (AUTHOR), Polier, Gernot⁵ (AUTHOR), Kurimoto, Akiko¹ (AUTHOR), Tomoe, Yumiko¹ (AUTHOR), Toyota, Akiko¹ (AUTHOR), Yoneyama, Tomoko² (AUTHOR), Imai, Emi² (AUTHOR), Watanabe, Kenji¹ (AUTHOR), Hamada, Tomoaki¹ (AUTHOR), Kanada, Ryutaro¹ (AUTHOR)

Source: Cancer Cell International. 2/25/2023, Vol. 23 Issue 1, p1-16. 16p.

Subject Terms: *ACUTE leukemia, *CYTARABINE, *SUCCINIC acid, *DRUG therapy, *LYMPHOBLASTIC leukemia, *ACUTE myeloid leukemia, *CELL differentiation

Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors.

Authors: Bewersdorf, Jan Philipp¹ (AUTHOR), Shallis, Rory M.² (AUTHOR), Derkach, Andriy³ (AUTHOR), Goldberg, Aaron D.¹ (AUTHOR), Stein, Anthony⁴ (AUTHOR), Stein, Eytan M.¹ (AUTHOR), Marcucci, Guido⁴ (AUTHOR), Zeidan, Amer M.² (AUTHOR), Shimony, Shai⁵ (AUTHOR), DeAngelo, Daniel J.⁵ (AUTHOR), Stone, Richard M.⁵ (AUTHOR), Aldoss, Ibrahim⁴ (AUTHOR), Ball, Brian J.⁴ (AUTHOR), Stahl, Maximilian⁵ (AUTHOR)

Source: Leukemia & Lymphoma. Jan2023, Vol. 64 Issue 1, p188-196. 9p.

Subject Terms: *CYTARABINE, *ACUTE myeloid leukemia, *SALVAGE therapy, *VENETOCLAX, *OVERALL survival

Degradation of cytostatics methotrexate and cytarabine through physico-chemical and advanced oxidative processes: influence of pH and combined processes on the treatment efficiency.

Authors: Pimentel-Almeida, Wendell¹ (AUTHOR), Testolin, Renan C.² (AUTHOR), Gaspareto, Patrick³ (AUTHOR), Gerlach, Otto M. S.⁴ (AUTHOR), Pereira-Filho, Jurandir¹ (AUTHOR), Sanches-Simões, Eric¹ (AUTHOR), Corrêa, Albertina X. R.¹ (AUTHOR), Almerindo, Gizelle I.⁴ (AUTHOR), González, Sergio Y. G.⁵ (AUTHOR), Somensi, Cleder A.⁶ (AUTHOR), Radetski, Claudemir M.¹ (AUTHOR) radetski@univali.br

Source: Environmental Technology. Aug2024, Vol. 45 Issue 20, p4053-4061. 9p.

Subject Terms: *Aquatic organisms, Methotrexate, Antineoplastic agents, Cytarabine, Ozonolysis, Test methods

Clinical features, treatment, and outcome of juvenile dogs with meningoencephalitis of unknown etiology.

Authors: Galer, Jack¹ (AUTHOR) jackagaler@gmail.com, Forward, Alexander K.¹ (AUTHOR), Hughes, Jonathan¹ (AUTHOR), Crawford, Abbe Harper² (AUTHOR), Behr, Sebastien³ (AUTHOR), Cherubini, Giunio Bruto^4,5 (AUTHOR), Cornelis, Ine⁶ (AUTHOR), Royaux, Emilie¹ (AUTHOR)

Source: Journal of Veterinary Internal Medicine. Jul/Aug2024, Vol. 38 Issue 4, p2214-2220. 7p.

Subject Terms: *CYTARABINE, *SURVIVAL rate, *SURVIVAL analysis (Biometry), *DEATH rate, *PROGNOSIS

Fluorescent Clade IIb Lineage B.1 Mpox Viruses for Antiviral Screening.

Authors: Alvarez-de Miranda, Francisco Javier¹ (AUTHOR), Martín, Rocío¹ (AUTHOR), Alcamí, Antonio¹ (AUTHOR), Hernáez, Bruno¹ (AUTHOR) bhernaez@cbm.csic.es

Source: Viruses (1999-4915). Feb2025, Vol. 17 Issue 2, p253. 12p.

Subject Terms: *MONKEYPOX, *VIRAL transmission, *CYTARABINE, *FLUORESCENT proteins, *VIRAL genomes

EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax.

Authors: Fooks, Katie^1,2 (AUTHOR), Galicia-Vazquez, Gabriela¹ (AUTHOR), Gife, Victor^3,4 (AUTHOR), Schcolnik-Cabrera, Alejandro³ (AUTHOR), Nouhi, Zaynab³ (AUTHOR), Poon, William W. L.^1,2 (AUTHOR), Luo, Vincent^1,2 (AUTHOR), Rys, Ryan N.^1,5 (AUTHOR), Aloyz, Raquel^1,2,6 (AUTHOR), Orthwein, Alexandre^1,2,6,7 (AUTHOR), Johnson, Nathalie A.^1,2,6 (AUTHOR), Hulea, Laura^3,4,8 (AUTHOR) laura.hulea@umontreal.ca, Mercier, Francois E.^1,2 (AUTHOR) francois.mercier@mcgill.ca

Source: Journal of Experimental & Clinical Cancer Research (17569966). 12/9/2022, Vol. 41 Issue 1, p1-19. 19p.

Subject Terms: *CYTARABINE, *VENETOCLAX, *ACUTE myeloid leukemia, *KREBS cycle, *HEMATOLOGIC malignancies, *HOMEOSTASIS

An integrated experimental and simulation study on the loading of cytarabine in a biocompatible zinc imidazole metal–organic framework.

Authors: Singh, Chitrangda^1,2 (AUTHOR), Jha, Chandan Bhogendra¹ (AUTHOR), Kumar, Navneet³ (AUTHOR), Singh, Ragini⁴ (AUTHOR), Ojha, Himanshu¹ (AUTHOR), Upadhyayula, Sreedevi² (AUTHOR) sreedevi@chemical.iitd.ac.in, Varshney, Raunak¹ (AUTHOR), Mathur, Rashi¹ (AUTHOR) rashimathur07@gmail.com

Source: Journal of Materials Science. Oct2022, Vol. 57 Issue 39, p18561-18577. 17p. 3 Black and White Photographs, 3 Diagrams, 4 Charts, 9 Graphs.

Subject Terms: *METAL-organic frameworks, *CYTARABINE, *ADSORPTION isotherms, *DRUG storage, *MONTE Carlo method

Rovatirelin ameliorates motor dysfunction in the cytosine arabinoside‐induced rat model of spinocerebellar degeneration via acetylcholine and dopamine neurotransmission.

Authors: Ijiro, Tomoyuki¹ (AUTHOR) tomoyuki_ijiro@pharm.kissei.co.jp, Yaguchi, Atsushi¹ (AUTHOR), Yokoyama, Ayaka¹ (AUTHOR), Kiguchi, Sumiyoshi¹ (AUTHOR)

Source: Clinical & Experimental Pharmacology & Physiology. Sep2022, Vol. 49 Issue 9, p950-958. 9p. 5 Graphs.

Subject Terms: *FRIEDREICH'S ataxia, *CYTARABINE, *DOPAMINE antagonists, *ACETYLCHOLINE, *THYROTROPIN releasing factor, *DOPAMINE, *NEURAL transmission, *ANIMAL disease models

Geographic Terms: NAGOYA-shi (Japan), JAPAN

Efficacy of conventional‐dose cytarabine, idarubicin and thioguanine versus intermediate‐dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long‐term results of the prospective randomized nationwide AML‐2003 study by the Finnish Leukemia Group

Authors: Kolonen, Aarne¹ (AUTHOR) aarne.kolonen@fimnet.fi, Sinisalo, Marjatta¹ (AUTHOR), Huhtala, Heini² (AUTHOR), Rimpiläinen, Johanna¹ (AUTHOR), Rintala, Hannele¹ (AUTHOR), Sankelo, Marja¹ (AUTHOR), Koivunen, Elli¹ (AUTHOR), Silvennoinen, Raija¹ (AUTHOR), Räty, Riikka³ (AUTHOR), Ruutu, Tapani³ (AUTHOR), Volin, Liisa³ (AUTHOR), Porkka, Kimmo³ (AUTHOR), Jantunen, Esa⁴ (AUTHOR), Nousiainen, Tapio⁴ (AUTHOR), Kuittinen, Taru⁴ (AUTHOR), Penttilä, Karri⁴ (AUTHOR), Pyörälä, Marja⁴ (AUTHOR), Säily, Marjaana⁵ (AUTHOR), Koistinen, Pirjo⁵ (AUTHOR), Kauppila, Marjut⁶ (AUTHOR)

Source: European Journal of Haematology. Sep2022, Vol. 109 Issue 3, p257-270. 14p.

Subject Terms: *ACUTE myeloid leukemia, *CYTARABINE, *IDARUBICIN, *LEUKEMIA, *INDUCTION chemotherapy

Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.

Authors: Kopmar, Noam E.¹ (AUTHOR), Gooley, Ted² (AUTHOR), Curley, Niall¹ (AUTHOR), Russell, Kathryn¹ (AUTHOR), Shaw, Carole³ (AUTHOR), Schonhoff, Kelda¹ (AUTHOR), Lim, John¹ (AUTHOR), Halpern, Anna B.^1,3 (AUTHOR), Walter, Roland B.^1,3,4,5 (AUTHOR), Scott, Bart L.^1,3 (AUTHOR), Appelbaum, Jacob¹ (AUTHOR), Hendrie, Paul C.¹ (AUTHOR), Estey, Elihu H.^1,3 (AUTHOR), Percival, Mary-Elizabeth M.^1,3 (AUTHOR)

Source: Leukemia & Lymphoma. May2023, Vol. 64 Issue 5, p1057-1059. 3p.

Subject Terms: *CYTARABINE, *MITOXANTRONE, *GRANULOCYTE-colony stimulating factor, *TUMORS, *BLAST injuries